These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29071198)

  • 1. Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.
    Li R; Zheng K; Yuan C; Chen Z; Huang M
    Nanotheranostics; 2017; 1(4):346-357. PubMed ID: 29071198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigations of the targeting pathway of nanomedicines toward tumor.
    Tao Y; Lan X; Zhang Y; Qing G; Wang J; Xiao Y; Chen H; Liu L; Liang XJ; Guo W
    Expert Opin Drug Deliv; 2022 Aug; 19(8):985-996. PubMed ID: 35929954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging.
    Zhou X; Zheng K; Li R; Chen Z; Yuan C; Hu P; Chen J; Xue J; Huang M
    Acta Biomater; 2015 Sep; 23():116-126. PubMed ID: 26004218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of nanomaterials in vivo: blood circulation and organ clearance.
    Wang B; He X; Zhang Z; Zhao Y; Feng W
    Acc Chem Res; 2013 Mar; 46(3):761-9. PubMed ID: 23964655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.
    Izci M; Maksoudian C; Manshian BB; Soenen SJ
    Chem Rev; 2021 Feb; 121(3):1746-1803. PubMed ID: 33445874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the relationship between nanomaterial hazard and physicochemical properties: Informing the exploitation of nanomaterials within therapeutic and diagnostic applications.
    Johnston H; Brown D; Kermanizadeh A; Gubbins E; Stone V
    J Control Release; 2012 Dec; 164(3):307-13. PubMed ID: 22940205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
    Tummalapalli P; Gondi CS; Dinh DH; Gujrati M; Rao JS
    Int J Oncol; 2007 Jul; 31(1):5-17. PubMed ID: 17549400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modal Mn-Zn ferrite nanocrystals for magnetically-induced cancer targeted hyperthermia: a comparison of passive and active targeting effects.
    Xie J; Yan C; Yan Y; Chen L; Song L; Zang F; An Y; Teng G; Gu N; Zhang Y
    Nanoscale; 2016 Oct; 8(38):16902-15. PubMed ID: 27427416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
    Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
    Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
    Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
    J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance Pathways and Tumor Targeting of Imaging Nanoparticles.
    Yu M; Zheng J
    ACS Nano; 2015 Jul; 9(7):6655-74. PubMed ID: 26149184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
    Maruyama K
    Adv Drug Deliv Rev; 2011 Mar; 63(3):161-9. PubMed ID: 20869415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging.
    Pant K; Neuber C; Zarschler K; Wodtke J; Meister S; Haag R; Pietzsch J; Stephan H
    Small; 2020 Feb; 16(7):e1905013. PubMed ID: 31880080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.